Immunological approaches as therapy for Alzheimer's disease

Expert Opinion on Biological Therapy

Volumn 2, Issue 8, 2002, Pages 907-917

  Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Amyloid plaques; Anti aggregating antibodies; Conformation; Immunisation

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-30]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; FC RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10D5; MONOCLONAL ANTIBODY 266; MONOCLONAL ANTIBODY 3D6; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BEHAVIOR; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; CORRELATION ANALYSIS; DEMENTIA; DISEASE SEVERITY; FEVER; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MICROGLIA; MUSCLE STIFFNESS; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; ANIMALS; BEHAVIOR, ANIMAL; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA;

MUS MUSCULUS;

EID: 0036914592     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.8.907     Document Type: Review

References (85)

1. Carrell RW, Lomas DA: Conformational disease. Lancet (1997) 35:134-138.
2. Kaytor MD, Warren ST: Aberrant protein deposition and neurological disease. J. Biol. Chem. (1999) 274:37507-37510.
3. Wetzel R: Mutations and off-pathway aggregation of proteins. Trends Biotechnol. (1994) 12:193-198.
4. Kelly JW: Amyloid fibril formation and protein misassembly: A structural quest for insights into amyloid and prion diseases. Structure (1997) 5:595-600.
5. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW: Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Nat. Acad. Sci. USA (1996) 93:15051-15056.
6. Blaney JM, Jorgensen EC, Connolly ML et al.: Computer graphics in drug design: Molecular modeling of thyroid hormone-prealbumin interactions. J. Med. Chem. (1982) 25:785-790.
7. Frauenfelder H, Petsko GA, Tsernoglou D: Temperature-dependent x-ray diffraction as a probe of protein structural dynamics. Nature (1979) 280:558-563.
8. Karplus M, Petsko GA: Molecular dynamics simulations in biology. Nature (1990) 347:632-639.
9. Solomon B, Balas N: Thermostabilization of Carboxypeptidase A by interaction with its monoclonal antibodies. Biotechnol. and Appl. Biochem. (1991) 14:202-211.
10. Katzav T, Hanan E, Solomon B: Effect of monoclonal antibodies in preventing Carboxypeptidase A aggregation. Appl. Biochem. Biotechnol. (1996) 2:227-230.
11. Blond S, Goldberg M: Partly native epitopes are already present on early intermediates in the folding of tryptophan synthase. Proc. Natl. Acad. Sci. USA (1987) 84:1147-1151.
12. Carlson JD, Yarmush ML: Antibody assisted protein refolding. Biol Technology (1992) 10:86-91.
13. Solomon B, Schwartz F: Chaperone-like effect of monoclonal antibodies on refolding of heat-denatured Carboxypeptidase A. J. Mol. Recognit. (1995) 8:72-76.
14. Silen JL, Agard DA: The alpha-lyric protease pro-region does not require a physical linkage to activate the protease domain in vivo. Nature (1989) 341:462-464.
15. Hebert LE, Beckett LA, Scherr PA, Evans DA: Annual incidence of Alzheimer's disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. (2001)15:169-173.
16. Selkoe DJ: The molecular pathology of Alzheimer's disease. Neuron (1991) 6:487-498.
17. Busciglio J, Lorenzo A, Yeh J, Yankner BA: β-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron (1995) 14:879-888. Evidence of involvement of amyloid plaques in neurofibrillary tangle formation.
18. Gotz J, Probst A, Spillantini MG et al.: Somatodentritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. (1995) 14:1304-1313. Evidence of involvement of amyloid plaques in neurofibrillary tangles formation.
19. Lewis J, Dickson DW, Lin WL et al.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 293:1487-1491. Evidence of involvement of amytoid plaques in neurofibrillary tangle formation.
20. Hardy J, Duff K. & Hardy KG, Perez-Tur J, Hutton M: Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Nat. Neurosci. (1998) 1:355-358. Evidence of involvement of amyloid plaques in neurofibrillary tangle formation.
21. Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. (1991) 12:383-388.
22. Selkoe DJ: Amyloid β protein and the genetics of Alzheimer's disease. J. Biol. Chem. (1996) 271:18295-18298.
23. Hardy J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. (1998) 1:355-358.
24. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science (2002) 297:353-356. This is an excellent updated review which provides comprehensive and timely information on therapeutics based on amyloid hypothesis.
25. Chartier-Harlin MC, Crawford F, Houlden H et al.: Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature (1991) 353:844-846.
26. Goate A, Chartier-Harlin MC, Mullan M et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349:704-706.
27. Mullan M, Crawford F, Axelman K et al.: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of betaamyloid. Nat. Genet. (1992a) 1:345-347.
28. Mullan M, Houlden H, Windelspecht M et al.: A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 15, proximal to the alpha-1-antichymotrypsin gene. Nat. Genet. (1992b) 2:340-342.
29. Levy-Lahad E, Wasco W, Poorkaj P et al.: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 269:973-977.
30. Sherrington R, Rogaev EI, Liang Y et al.: Cloning of a gene bearing missense mutations in early-onset Alzheimer's disease. Nature (1995) 375:754-760.
31. Sabbagh MN, Galasko D, Thal LJ: β-amyloid and treatment opportunities for Alzheimer's disease. Alzheimer's Dis. Rev. (1998) 3:1-19.
32. Maggio JE, Mantyh PW: Brain amyloid - A physicochemical perspective. Brain Pathol. (1996) 6:147-162. This study suggests in vitro modulation of β-amyloid formation by various external factors.
33. Kirshenbaum K, Daggett V: pH-dependent conformations of the amyloid β (1-28) peptide fragment explored using molecular dynamics. Biochemistry (1995) 34:7629-7639.
34. Barrow CJ, Zagorski MG: Solution structures of β-peptide and its constituent fragments: Relation to amyloid deposition. Science (1991) 253:179-182.
35. Soto C, Castano EM, Frangione B, Inestrosa, NC: The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation. J. Biol. Chem. (1995) 270:3063-3067.
36. Soto C, Kindy MS, Baumann M, Frangione B: Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun. (1996) 226(3):672-680.
37. Lorenzo A, Yankner BA: Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA (1994) 1:12243-12247.
38. Howlett, DR, Jennings KH, Lee DC et al.: Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration (1995) 4:23-32.
39. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B: Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. (1994) 145(5):1030-1035.
40. Solomon B, Koppel R, Hanan E, Katzav T: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer's β-amyloid peptide. Proc. Natl. Acad. Sci. USA (1996) 93(1):452-455. This is the first demonstration that mAbs can prevent amyloid formation.
41. Solomon B, Koppel R, Frankel D, Hanan-Aharon E: Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA (1997) 94:4109-4112. This is the first demonstration that site-directed antibodies dissolve already formed amyloid fibrils.
42. Hanan E, Solomon B: Protective effect of monoclonal antibodies against Alzheimer's β-amyloid aggregation. Amyloid: Int. J. Exp. Clin. Invest. (1996) 3:130-133.
43. Frenkel D, Solomon B, Benhar I: Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single-chain antibody. J. Neuroimmunol. (2000) 106:23-31. Antibodies devoid of Fc region exhibit anti-aggregating properties preventing Aβ neurotoxicity.
44. Frenkel D, Balass M, Solomon B: N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies. J. Neuroimmunol. (1998) 8:85-90.
45. Frenkel D, Balass M, KachalskyKatzir E, Solomon B: High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol. (1999) 95:136-142. The study emphasises the key role of EFRH sequence in modulation of AβP conformation.
46. Van Leuven F: Single and multiple transgenic mice as models for Alzheimer's disease. Prog. Neurobiol. (2000) 61(3):305-312.
47. Moore CL, Wolfe MS: Inhibition of β-amyloid formation as a therapeutic strategy. Expert Opin. Ther. Patents (1999) 9(2):135-146.
48. Games D, Adams D, Alessandrini R et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 373:523-527.
49. Schenk D, Barbour R, Dunn W et al.: Immunization with amyloid-β attenuates Alzheimer's disease-like pathology in the PDAPP mouse. Nature (1999) 400:173-177. First in vivo demonstration that anti-β-amyloid antibodies reduce amyloid plaque in transgenic mice.
50. Weiner HL, Lemere CA, Maron R et al.: Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. (2000) 48:567-579.
51. Lemere CA, Maron R, Spooner ET et al.: Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PDAPP mice. Ann. NY Acad. Sci. (2000) 920:328-331.
52. Lemere CA, Maron R, Selkoe DJ, Weiner H: Nasal vaccination with β-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. (2001) 20:705-711.
53. Gurwitz D: Immunization for Alzheimer's disease: Yet closer to clinical trials. Trends Immunol. (2001) 22(10):542-543.
54. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T: Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. (2001) 159:439-447.
55. Hsiao K, Chapman P, Nilsen S et al.: Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science (1996) 274:99-102.
56. Frenkel D, Katz O, Solomon B: Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. USA (2000) 97:11455-11459.
57. Scott JK, Smith GP: Searching for peptide ligands with an epitope library. Science (1990) 249:386-390.
58. Scott JK: Discovering peptide ligands using epitope libraries. Trends Biochem Sci (1992) 17(7):241-245.
59. Greenwood J, Willis EA, Perham NR: Multiple display of foreign peptides on a filamentous bacteriophage. J. Mol. Biol. (1991) 220:821-827.
60. Willis EA, Perham NR, Wraith D: Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage. Gene (1993) 128:79-83.
61. Bastein N, Trude M, Simard C: Protective immune responses induced by the immunization of mice with recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology (1997) 234:118-122.
62. Solomon B, Frenkel D: Vaccination towards prevention and treatment of Alzheimer's disease. Drugs of Today (2000) 36(9):655-663.
63. Frenkel D, Kariv N, Solomon B: Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine Elsevier (2001) 19:2615-2619.
64. Frenkel D, Solomon B: Towards Alzheimer's beta-amyloid vaccination. Biologicals (2001) 29:243-247.
65. Frenkel D, Dewachter I, Van Leuven, Solomon B: Reduction of Aβ amyloid by EFRH-phage immunization. Vaccine (2002) In Press.
66. Moechars D, Dewchter I, Lorent K et al.: Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem.(1999) 274:6483-6492.
67. Bard F, Cannon C, Barbour R et al.: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. (2000) 6:916-920. First evidence that peripheral administration of antibodies against beta-peptide cross BBB, decorate and dissolve plaque.
68. Bacskai BJ, Kajdasz ST, Christie RH et al.: Imaging of amyloid-B deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. (2001) 7:369-372. In vivo targeting of amyloid plaques by mAb and visualisation of clearance of plaque.
69. Demattos RB, Bales KR, CUMMINS DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA (2001) 17:8850-8855.
70. Janus C, Pearson J, Mclaurin J et al.: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979-982. First demonstration of correlation between improved behaviour and vaccination against AβP.
71. Morgan D, Diamond DM, Gottschall PE et al.: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982-985. First demonstration of correlation between improved behaviour and vaccination against AβP.
72. Holcomb L, Gordon MN, Mcgowan E et al.: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. (1998) 4:97-100.
73. Dodart JC, Bales KR, Gannon KS et al.: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. (2002) 5(5):452-457.
74. Wyss-Coray T, Lin C, Yan F et al.: TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. (2001) 7(5):612-874.
75. Bacskai BJ, Kajdasz ST, Megan E et al.: Non-fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. (2002) 22(18):7873-7878.
76. Demattos RB, Bales KR, Cummins DJ et al.: Brain to plasma amyloid-β efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 295:2264-2267.
77. Huang F, Buttini M, Wyss-Coray T et al.: Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am. J. Pathol. (1999) 155:1741-1747.
78. Bornemann KD, Wiederhold KH, Pauli C et al.: Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am. J. Pathol. (2001) 158:63-73.
79. Munch G, Thome J, Foley P, Schinzel R, Riederer P: Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res. Rev. (1997) 23:134-143.
80. Tabaton M, Perry G, Smith M et al.: Is amyloid beta-protein glycated in Alzheimer's disease? NeuroReport. (1997) 8:907-909.
81. Schenk D, Seubert P, Ciccarelli RB: Immunotherapy with β-amyloid for Alzheimer's disease: A new frontier. DNA Cell Biol. (2001) 20:679-681.
82. Solomon B: Imunotherapeutic strategies towards prevention and treatment of Alzheimer's disease. DNA and Cell Biology (2001) 20:697-703.
83. Takai T: Roles of Fc receptors in autoimmunity. Nature Reviews (2002) 2:580-592.
84. Samuelsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 291:484-486.
85. Frenkel D, Solomon B: Filamentous phage as vector-mediated antibody delivery to the brain. Proc. Natl. Acad. Sci. USA (2002) 99:5675-5679.